Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Seer, Inc.
  6. Summary
    SEER   US81578P1066

SEER, INC.

(SEER)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/10/2022 01/11/2022 01/12/2022 01/13/2022 01/14/2022 Date
19.02(c) 20.5(c) 20.5(c) 19.29(c) 19.59(c) Last
458 653 548 322 434 644 684 193 599 504 Volume
+1.98% +7.78% 0.00% -5.90% +1.56% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 5,75 M - -
Net income 2021 -72,3 M - -
Net cash position 2021 490 M - -
P/E ratio 2021 -12,1x
Yield 2021 -
Sales 2022 14,8 M - -
Net income 2022 -86,5 M - -
Net cash position 2022 427 M - -
P/E ratio 2022 -14,8x
Yield 2022 -
Capitalization 1 209 M 1 209 M -
EV / Sales 2021 125x
EV / Sales 2022 52,7x
Nbr of Employees 60
Free-Float -
More Financials
Company
Seer, Inc. is a life sciences technology company. The Company enables scientific outcomes by commercializing products for researchers to unlock biological information. Its initial product, the Proteograph Product Suite (Proteograph), uses its engineered nanoparticle (NP) technology to provide access across the proteome. Its Proteograph Product Suite is comprised of consumables, an automation instrument and software.... 
Sector
Office Equipment
Calendar
03/28Earnings Release
More about the company
Ratings of Seer, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D
More Ratings
All news about SEER, INC.
01/10UPDATED : Seer Announces Broad Commercial Release of the Proteograph™áProduct Suite ..
GL
01/10UPDATED : Seer Announces Broad Commercial Release of the Proteograph™áProduct Suite ..
GL
01/10SEER : JP Morgan Healthcare Conference 2022 Presentation
PU
01/10Seer, Discovery Life Sciences and SCIEX Announce First-Of-Its-Kind Proteogenomics Conso..
AQ
01/10Seer, Discovery Life Sciences and SCIEX Announce First-Of-Its-Kind Proteogenomics Conso..
CI
01/10Seer Announces Broad Commercial Release of the Proteograph™ Product Suite andáLau..
AQ
01/10Seer Announces Broad Commercial Release of the Proteograph™ Product Suite
CI
2021Seer to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference
AQ
2021ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Seer, Inc. Investors with Losses ..
PR
2021Dynamics SPAC Signs Business Combination Deal to Take Senti Biosciences Public; Shares ..
MT
2021SEER, INC.(NASDAQGS : SEER) added to NASDAQ Biotechnology Index
CI
2021SEER : Appoints Meeta Gulyani to its Board of Directors - Form 8-K
PU
2021SEER, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits ..
AQ
2021Seer Appoints Meeta Gulyani to its Board of Directors
AQ
2021Seer, Inc. Appoints Meeta Gulyani to its Board of Directors
CI
More news
News in other languages on SEER, INC.
01/10Seer, Discovery Life Sciences et SCIEX annoncent la création d'un consortium protéogéno..
01/10Seer annonce le lancement commercial à grande échelle de la suite de produits Proteogra..
2021Dynamics SPAC signe un accord de regroupement d'entreprises pour faire entrer Senti Bio..
2021Earnings Flash (SEER) SEER annonce un chiffre d'affaires de 2,2 millions de dollars pou..
2021MISE À JOUR SECTORIELLE : Les soins de santé en hausse en fin d'après-midi mais les biotec..
More news
Analyst Recommendations on SEER, INC.
More recommendations
Chart SEER, INC.
Duration : Period :
Seer, Inc. Technical Analysis Chart | SEER | US81578P1066 | MarketScreener
Technical analysis trends SEER, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 19,59 $
Average target price 48,67 $
Spread / Average Target 148%
EPS Revisions
Managers and Directors
Omid C. Farokhzad Chairman & Chief Executive Officer
Omead Ostadan President, Chief Operating Officer & Director
David R. Horn Chief Financial Officer
David L. Hallal Lead Independent Director
Robert S. Langer Director
Sector and Competitors
1st jan.Capi. (M$)
SEER, INC.-14.12%1 209
METTLER-TOLEDO INTERNATIONAL INC.-11.40%34 772
TECAN GROUP LTD.-21.19%6 080
JEOL LTD.-21.98%3 213
NINGBO YONGXIN OPTICS CO., LTD.3.58%2 181
OLINK HOLDING AB (PUBL)-30.93%1 496